Bellerophon Therapeutics Inc (NASDAQ:BLPH) has been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Analysts have set a twelve-month consensus price target of $2.75 for the company and are predicting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also assigned Bellerophon Therapeutics an industry rank of 83 out of 255 based on the ratings given to related companies.

Several analysts recently issued reports on the company. Maxim Group reissued a buy rating and set a $2.00 target price on shares of Bellerophon Therapeutics in a research note on Thursday, November 7th. HC Wainwright reaffirmed a buy rating and set a $3.00 price objective on shares of Bellerophon Therapeutics in a report on Wednesday, December 18th. Finally, ValuEngine raised shares of Bellerophon Therapeutics from a sell rating to a hold rating in a report on Thursday, December 12th.

Shares of BLPH stock opened at $0.35 on Thursday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.96 and a quick ratio of 1.96. Bellerophon Therapeutics has a one year low of $0.31 and a one year high of $0.79. The companys fifty day moving average price is $0.36 and its 200-day moving average price is $0.49. The company has a market capitalization of $24.10 million, a price-to-earnings ratio of -2.34 and a beta of -0.11.

Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.06) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.07) by $0.01. Equities research analysts expect that Bellerophon Therapeutics will post -0.23 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Bellerophon Therapeutics by 15.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,152,175 shares of the biotechnology companys stock valued at $690,000 after purchasing an additional 158,000 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Bellerophon Therapeutics by 8.9% in the second quarter. Renaissance Technologies LLC now owns 1,434,538 shares of the biotechnology companys stock worth $860,000 after purchasing an additional 116,862 shares during the last quarter. Finally, LPL Financial LLC increased its holdings in shares of Bellerophon Therapeutics by 22.1% in the second quarter. LPL Financial LLC now owns 130,800 shares of the biotechnology companys stock worth $78,000 after purchasing an additional 23,650 shares during the last quarter. Institutional investors and hedge funds own 50.54% of the companys stock.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.

Featured Article: Google Finance Portfolio

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Excerpt from:
Bellerophon Therapeutics Inc (NASDAQ:BLPH) Given Consensus Recommendation of Strong Buy by Brokerages - Riverton Roll